Jennifer Ruddock | Head of Investor Relations |
Howard Robin | President and CEO |
Gil Labrucherie | Chief Financial Officer |
Stephen Doberstein | Head of R&D |
Jonathan Zalevsky | Chief Scientific Officer |
Mary Tagliaferri | Chief Medical officer |
Chris Shibutani | Cowen |
Jessica Fye | JPMorgan |
Tyler Van Buren | Piper Jaffray |
Paul Choi | Goldman Sachs |
Alex Lim | Mizuho |
Bert Hazlett | BTIG |
Andy Hsieh | Blair |
David Steinberg | Jefferies |
George Farmer | BMO Capital Markets |
Daina Graybosch | SVB Leerink |
Good day, ladies and gentlemen, and welcome to the Nektar Therapeutics Q2 2019 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call may be recorded.
I would now like to introduce your host for today's conference, Ms. Jennifer Ruddock, Head of Investor Relations. Ma'am, you may begin.